In the past decade, PD-1/PD-L1 ICIs or PD-1/PD-L1-targeted therapy has been shown to improve the overall survival rate in several cancer types, including NSCLC patients [5,6]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.